Pamela Craven, MD
Cardiovascular Disease · Oklahoma City, OKNPI 1144214370
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,016 of the $4,250 with a category attached, or 71.0%. 23 manufacturers reported payments, led by Kaneka Medical America LLC at 28.8% of the total.
Across 158 payments — averaging $26.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kaneka Medical America LLC$1K
- Boehringer Ingelheim$677
- Amgen$432
- E.r. Squibb & Sons, L.L.C.$273
- AstraZeneca$269
- Novartis$192
- plus $1K from 17 others
Across 8 payments — averaging $657.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cvrx, Inc.$5K
What the payments were for
- Consulting fees$2857%
- Speaking & faculty fees$94122%
- Food & beverage$3,01671%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kaneka Medical America LLC | 2 | $1,226 |
| Boehringer Ingelheim | 27 | $677 |
| Amgen | 42 | $432 |
| E.r. Squibb & Sons, L.L.C. | 11 | $273 |
| AstraZeneca | 9 | $269 |
| Novartis | 11 | $192 |
| Abbott | 3 | $183 |
| Johnson & Johnson | 15 | $178 |
| Regeneron Healthcare Solutions, Inc. | 7 | $168 |
| Pfizer | 6 | $132 |
| Alnylam Pharmaceuticals Inc. | 4 | $90 |
| Philips North America LLC | 2 | $88 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $68 |
| Daiichi Sankyo Inc. | 2 | $42 |
| Impulse Dynamics (USA) Inc. | 2 | $41 |
| Novo Nordisk | 2 | $36 |
| Kestra Medical Technology Services, Inc. | 1 | $33 |
| Amicus Therapeutics, Inc. | 1 | $26 |
| Vifor Pharma, Inc. | 2 | $25 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Bayer | 1 | $19 |
| Boston Scientific | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIPOSORBER$1,226
- JARDIANCE$230
- CARDIOMEMS$131
- WAINUA$122
- CAMZYOS$104
How this compares
$4,250 in reported general payments places this provider in the 60th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndaqelTafamidis Meglumine | 52 | $1,130,284 |
| EliquisApixaban | 952 | $974,490 |
| EntrestoSacubitril/Valsartan | 409 | $544,943 |
| VyndamaxTafamidis | 22 | $504,590 |
| JardianceEmpagliflozin | 424 | $459,203 |
| CamzyosMavacamten | 30 | $238,298 |
| Repatha SureclickEvolocumab | 197 | $192,885 |
| XareltoRivaroxaban | 148 | $168,276 |
| FarxigaDapagliflozin Propanediol | 56 | $61,001 |
| OzempicSemaglutide | 39 | $44,150 |
| CorlanorIvabradine Hcl | 40 | $41,860 |
| Praluent PenAlirocumab | 38 | $40,618 |
| MounjaroTirzepatide | 30 | $30,166 |
| Rosuvastatin Calcium | 1,175 | $27,137 |
| MultaqDronedarone Hcl | 16 | $21,293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndaqel, Eliquis, Vyndamax | $132 | $2,609,3641,026 claims |
| NovartisEntresto | $192 | $544,943409 claims |
| Boehringer IngelheimJardiance | $677 | $459,203424 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $273 | $238,29830 claims |
| Johnson & JohnsonXarelto | $178 | $168,276148 claims |
| AstraZenecaFarxiga, Brilinta | $269 | $71,00372 claims |
| Novo NordiskOzempic | $36 | $44,15039 claims |
| AmgenCorlanor | $432 | $41,86040 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $20 | $18,33036 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Oklahoma City
- Aly El BanayosyOklahoma City$54K
- Dwight ReynoldsOklahoma City$47K
- Udho ThadaniOklahoma City$41K
- Robert SullivanOklahoma City$36K
- Reji PappyOklahoma City$25K
- Sandeep ChopraOklahoma City$15K
- Jered CookOklahoma City$14K
- William CollazoOklahoma City$11K
- Vinodh JeevananthamOklahoma City$11K
- Niraj PrasadOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.